Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Set To End on December 25th

Alumis’ (NASDAQ:ALMS) lock-up period will expire on Wednesday, December 25th. Alumis had issued 13,125,000 shares in its public offering on June 28th. The total size of the offering was $210,000,000 based on an initial share price of $16.00. After the expiration of Alumis’ lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analysts Set New Price Targets

Several research analysts have commented on ALMS shares. Baird R W raised Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Robert W. Baird initiated coverage on Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Alumis in a report on Friday. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Alumis currently has a consensus rating of “Buy” and an average target price of $26.83.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $8.82 on Friday. The company has a fifty day moving average of $10.21. Alumis has a 52-week low of $7.66 and a 52-week high of $13.53.

Hedge Funds Weigh In On Alumis

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Alumis in the 3rd quarter worth approximately $27,000. MetLife Investment Management LLC acquired a new stake in shares of Alumis in the third quarter valued at about $89,000. Barclays PLC acquired a new stake in shares of Alumis in the third quarter valued at about $197,000. Maven Securities LTD acquired a new position in Alumis during the second quarter worth about $332,000. Finally, State Street Corp purchased a new position in Alumis during the third quarter worth about $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.